## UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 1, 2017

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

MacroGenics, Inc.

File No. 333-190994 - CF#35267

\_\_\_\_\_

MacroGenics, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on September 4, 2013.

Based on representations by MacroGenics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.16 through July 3, 2022 Exhibit 10.16.1 through July 3, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary